Indoco Remedies Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xclipqpdgqgiiohxn86jwrox.pdf

Key Takeaways


Domestic Formulations: The H2 Rebound Bet

Aditi Panandikar: "This was a very challenging year for us for target setting for India business... we have now revised it strategically for the second half and I therefore expect much better performance."

International Formulations: US and Europe Drive Growth

Sundeep Bambolkar: "We deployed a very careful strategy while hedging the euro and pound with the result our hedging has been near to perfect. I would not bores too much about it because things could go wrong in subsequent quarters, so I will be a very little careful on my words, but at least for the time being we are on good track."

Margin Trajectory: Gross Margin Recovery, Europe the Lever

Sundeep Bambolkar: "Right now margins are tottering around 9.5%, 10% of EBITDA, but going ahead within three quarters from now onwards I hope to see EBITDAs of 14%, 15% minimum."

Operational Milestones: SAP Go-Live and Pipeline Build


Guidance & Commitments

CommitmentSpecificsTimeline
India full-year revenue growthAt least 5% reported growth over FY22 (Rs.840–845 Crores)FY23
H2 domestic revenue skewH2 to contribute more than 50% of full-year India revenue (vs typical 45%)FY23
Europe EBITDA margin improvementFrom 9.5–10% to 14–15% minimumWithin three quarters
Full-year US revenueAt least Rs.300 CroresFY23
Full-year EBITDA margin~20%FY23
South Africa quarterly revenueDouble from Rs.3.5 Crores per quarterWithin two quarters
South Africa tender business~Rs.60 Crores per annumStarting April 2023
Micro Labs plant utilization70% occupanciesBy December 2023
CRO external business capacityDouble from current levelsIn a couple of months
CapexControlled to Rs.125 CroresFY23
Long-term margin ambitionBeat 25%In three years
Long-term revenue ambitionRs.5,000 CroresIn five years

Key Metrics

MetricQ2 FY23
Net revenue₹404.6 cr, +8.6% YoY
Domestic formulation revenue₹208.5 cr, -2.4% YoY; domestic branded business 55% of total revenue
International formulation revenue₹174 cr, +28.5% YoY
US business revenue₹69.3 cr, +44.7% YoY
Europe business revenue₹74.7 cr, +25.2% YoY
Emerging markets revenue₹26.5 cr, +9.5% YoY
API business revenue₹18.3 cr, -7.1% YoY
EBITDA margin21.7%, vs 23.2% YoY; EBITDA ₹87.8 cr vs ₹86.3 cr
PAT margin12.3%, vs 11.2% YoY; PAT ₹49.6 cr vs ₹41.6 cr
EPS₹5.39, vs ₹4.51 YoY
Gross margin70.5%, vs 67–67.5% QoQ; down 200 bps YoY from normal level of 72%
India business full-year growth guidanceAt least 5%, on base of ₹803 cr, implying ₹840–845 cr
US business full-year revenue expectationAt least ₹300 cr
Europe business order book₹150 cr plus as of call date
Europe business EBITDA margin9.5–10%, expected to improve to 14–15% within three quarters
New product introductions contribution₹5 cr, 2.3% of domestic topline vs 0.8% YoY
Chronic therapy contribution~10% of India business; H1 chronic sales ~₹50 cr
Capex for FY23₹125 cr projected; H1 capex ₹90 cr+
R&D spend5% of sales, expected to stabilize around this level
MR productivity3.5, improved from 3 over last couple of years
One-time indirect tax expense₹7 cr, recognized in other expenses; excluding this, other expenses would have been ₹112 cr
Incremental exchange gain in other operating income₹13 cr
Effective domestic price hike~6%
US new launches in H1 FY233 (one ophthalmic, two injectable)
South Africa quarterly revenue₹3.5 cr, expected to double in two quarters; earlier tender business ₹60–70 cr per annum
Lacosamide injection US market size₹4.9 cr, grew from ₹4.3 cr within three months of Indoco's entry
Vision target₹5,000 cr in five years, set by first-line team